| 12/7/09 |
Merrimack Pharmaceuticals Acquires Hermes Biosciences, Inc. |
| 10/1/09 |
Merrimack Press Release: Sanofi-aventis and Merrimack Pharmaceuticals enter into a Worldwide Collaboration and Licensing Agreement on MM-121, an anti-ErbB3 monoclonal antibody |
| 10/1/09 |
Sanofi-aventis Press Release: Sanofi-aventis and U.S. Biotechnology company Merrimack enter into an Exclusive Global Collaboration and Licensing Agreement for a monoclonal antibody in Oncology |
| 9/21/09 |
Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development |
| 7/8/09 |
GTC Biotherapeutics Press Release: GTC Biotherapeutics In-Licenses Recombinant Human Alpha-Fetoprotein from Merrimack Pharmaceuticals |
| 7/6/09 |
Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1/2 Study of MM-111, a bispecific antibody to ErbB2/3 |
| 6/25/09 |
'Science Signaling' to Publish Paper on Therapeutically Targeting Erb3 to Treat Overexpressed or Mutated Oncogenes |
| 4/16/09 |
Merrimack Pharmaceuticals to Present Pre-Clinical Data on MM-121 and MM-111 at the Annual Meeting of the American Association for Cancer Research |
| 12/15/08 |
Merrimack Pharmaceuticals to Present at 27th Annual JP Morgan Healthcare Conference |
| 10/15/08 |
Merrimack Pharmaceuticals to Present at Lazard 5th Annual Healthcare Conference |
| 9/15/08 |
Merrimack Pharmaceuticals to Present at Oppenheimer 19th Annual Healthcare Conference |
| 8/15/08 |
Merrimack Pharmaceuticals to Present at UBS Global Life Sciences Conference |
| 8/11/08 |
Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist |
| 6/10/08 |
Merrimack Pharmaceuticals Raises $60 Million in Private Financing |
| 4/24/08 |
In vivo Safety and Efficacy Data on MM-121, Merrimack's Most Advanced Oncology Product, presented during the Annual Meeting of the American Association for Cancer Research |
| 3/14/08 |
Merrimack Pharmaceuticals Completes Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis |
| 11/29/07 |
Merrimack Pharmaceuticals Announces the Addition of Robert Gay to its Board of Directors |
| 7/23/07 |
Merrimack Pharmaceuticals Names William Slichenmyer, MD Senior Vice President & Chief Medical Officer |
| 6/26/07 |
Merrimack Pharmaceuticals Names Lisa Evrén Senior Vice President & Chief Financial Officer |
| 6/12/07 |
Merrimack Pharmaceuticals Receives U.S. Patent Covering Composition of Matter for Recombinant, Non-Glycosylated Human Alpha-fetoprotein; Extends Patent Protection of Lead Product, MM-093, into 2025 |
| 4/17/07 |
Merrimack Pharmaceuticals Initiates Enrollment in a Phase 2 Study of MM-093 in Patients with Rheumatoid Arthritis |
| 4/4/07 |
Merrimack Pharmaceuticals Initiates Enrollment in a Phase 2 Pilot Study of MM-093 in Patients with Autoimmune Uveitis |
| 3/26/07 |
Merrimack Pharmaceuticals to Present at CIBC Biotechnology and Specialty Pharmaceuticals Conference |
| 1/12/07 |
Merrimack Pharmaceuticals to Present at BIO CEO Conference |
| 12/15/06 |
Merrimack Pharmaceuticals to Present at JPMorgan Healthcare Conference |
| 10/17/06 |
Merrimack Pharmaceuticals to Present at CIBC Healthcare Conference |
| 9/12/06 |
Merrimack Pharmaceuticals to Present at BIO Investor Forum |
| 8/15/06 |
Merrimack Pharmaceuticals to Present at Bear Stearns Healthcare Conference |
| 7/17/06 |
Merrimack Pharmaceuticals Announces the Addition of Louis Weiner, M.D., to its Scientific Advisory Board |
| 5/15/06 |
Merrimack Pharmaceuticals Announces Two Additions to its Board of Directors |
| 5/3/06 |
Merrimack Pharmaceuticals Names Fazal Khan, Ph.D., Vice President of Manufacturing |
| 4/19/06 |
Merrimack Pharmaceuticals Completes Enrollment for Phase 2 Trial of MM-093 in Patients with Psoriasis |
4/3/06
|
Merrimack Pharmaceuticals Raises $65 Million in Private Financing |
| 2/28/06 |
Merrimack Pharmaceuticals Announces the Addition of Barrett Rollins, MD, PhD to its Scientific Advisory Board |
| 10/19/05 |
Merrimack
Pharmaceuticals Completes Enrollment for Phase 2 Trial of MM-093
in Patients with Rheumatoid Arthritis |
| 10/13/05 |
Merrimack Pharmaceuticals
Initiates Enrollment in a Phase 2 Study of MM-093 in Patients
with Psoriasis |
| 5/24/05 |
Merrimack Pharmaceuticals
Announces the Addition of Two New Members to its Scientific
Advisory Board. |
| 5/3/05 |
Merrimack Pharmaceuticals
Appoints Gary L. Crocker as Chairman of the Board. |
| 4/20/05 |
Merrimack Pharmaceuticals
Closes on $37 Million of Series D Equity and Loan Financing. |
| 3/3/05 |
Merrimack Pharmaceuticals
Initiates Enrollment in a Phase II Study of MM-093 in Patients
with Rheumatoid Arthritis. |
| 8/25/04 |
Merrimack
Pharmaceuticals Completes Enrollment For Phase IIa Study of
MM-093 in Patients with Rheumatoid Arthritis. |
| 7/20/04 |
Merrimack Pharmaceuticals
Names Dr. Brian L. Hamilton Vice President of Clinical and Regulatory
Affairs. |
| 6/1/04 |
Merrimack Pharmaceuticals
Begins Exploratory Collaboration with Novartis Institutes for
Biomedical Research. |
| 5/4/04 |
Merrimack Pharmaceuticals
Welcomes Gary L. Crocker to the Board of Directors. |
| 5/4/04 |
Merrimack Pharmaceuticals
Closes $28 Million in Series C Financing Round. |
| 3/25/04 |
Merrimack Pharmaceuticals
Awarded Second SBIR Grant. |
| 2/4/04 |
Merrimack Pharmaceuticals
Names Vincent F. Simmon as Chief Operating Officer. |
| 1/29/04 |
Merrimack Awarded SBIR
Grant for Cancer Drug Discovery. |
| 12/15/03 |
GTC Biotherapeutics
Takes Equity Position in Merrimack Pharmaceuticals as MM-093
Development Advances. |
| 11/19/03 |
Merrimack Pharmaceuticals
Completes Dosing in Phase I Study of Immunomodulator, MM-093. |
| 7/29/03 |
Merrimack Pharmaceuticals
Initiates Phase I Study of Immunomodulator, MM-093. |
| 1/3/03 |
GTC Biotherapeutics and Merrimack
Pharmaceuticals expand relationship to include rhAFP clinical
grade purification. |
| 10/23/02 |
GTC Biotherapeutics
and Merrimack Pharmaceuticals to Begin rhAFP Clinical Production. |
| 3/26/02 |
Merrimack Pharmaceuticals
elects Gary Frashier as Chairman of the Board of Directors. |
| 3/19/02 |
Merrimack Pharmaceuticals
welcomes Robert H. Rubin, MD to the Board of Directors. |
| 2/26/02 |
U.S. composition-of-matter
patent secures Merrimack Pharmaceuticals' rights to recombinant
human alpha-fetoprotein. |
| 2/20/02 |
Merger closes between Merrimack
Pharmaceuticals and Atlantic Biopharmaceuticals. |
| 9/4/01 |
Atlantic Biopharmaceuticals
names James Scibetta Executive Vice President and Chief Financial
Officer. |
